1. Home
  2. AIDX vs SNGX Comparison

AIDX vs SNGX Comparison

Compare AIDX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$1.01

Market Cap

12.6M

Sector

Health Care

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.40

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIDX
SNGX
Founded
N/A
1987
Country
United States
United States
Employees
14
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
11.2M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
AIDX
SNGX
Price
$1.01
$0.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
51.8K
1.6M
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.19
$0.28
52 Week High
$14.09
$6.23

Technical Indicators

Market Signals
Indicator
AIDX
SNGX
Relative Strength Index (RSI) 17.69 34.80
Support Level N/A $0.28
Resistance Level $1.66 $0.41
Average True Range (ATR) 0.15 0.04
MACD 0.02 0.03
Stochastic Oscillator 13.14 91.77

Price Performance

Historical Comparison
AIDX
SNGX

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: